{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:15:25Z","timestamp":1784556925733,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient\u2019s concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR\/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient\u2019s preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR\/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.<\/jats:p>","DOI":"10.1007\/s40520-022-02176-y","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T19:03:47Z","timestamp":1658430227000},"page":"1985-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach"],"prefix":"10.1007","volume":"34","author":[{"given":"Nicholas","family":"Fuggle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Manuel","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Concepci\u00f3n","family":"Prieto Yerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitnat","family":"Dincer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida K.","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Herrero-Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Laslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmila","family":"Matijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Maheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Pierre","family":"Radermecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Uebelhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Uebelhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Vlaskovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-0709","authenticated-orcid":false,"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/ard.2011.150078","volume":"70","author":"IK Haugen","year":"2011","unstructured":"Haugen IK, Englund M, Aliabadi P et al (2011) Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 70:1581\u20131586. https:\/\/doi.org\/10.1136\/ard.2011.150078","journal-title":"Ann Rheum Dis"},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/rheumatology\/ket267","volume":"52","author":"WY Kwok","year":"2013","unstructured":"Kwok WY, Kloppenburg M, Marshall M et al (2013) Comparison of clinical burden between patients with erosive hand osteoarthritis and inflammatory arthritis in symptomatic community-dwelling adults: the Keele clinical assessment studies. Rheumatology (Oxford). 52:2260\u20132267. https:\/\/doi.org\/10.1093\/rheumatology\/ket267","journal-title":"Rheumatology (Oxford)."},{"key":"2176_CR3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1136\/ard.2010.143016","volume":"70","author":"WY Kwok","year":"2011","unstructured":"Kwok WY, Kloppenburg M, Rosendaal FR et al (2011) Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. Ann Rheum Dis 70:1238\u20131242. https:\/\/doi.org\/10.1136\/ard.2010.143016","journal-title":"Ann Rheum Dis"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.joca.2011.08.009","volume":"19","author":"D Pereira","year":"2011","unstructured":"Pereira D, Peleteiro B, Ara\u00fajo J et al (2011) The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 19:1270\u20131285. https:\/\/doi.org\/10.1016\/j.joca.2011.08.009","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR5","unstructured":"Worldometer (2021). https:\/\/www.worldometers.info. Accessed Jan 2022"},{"key":"2176_CR6","unstructured":"United Nations WB. Population projections (2022). https:\/\/data.worldbank.org\/indicator\/SP.POP.GROW. Accessed Jan 2022"},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.joca.2014.07.015","volume":"22","author":"A Turkiewicz","year":"2014","unstructured":"Turkiewicz A, Petersson IF, Bj\u00f6rk J et al (2014) Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthritis Cartilage 22:1826\u20131832. https:\/\/doi.org\/10.1016\/j.joca.2014.07.015","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2018-213826","volume":"78","author":"M Kloppenburg","year":"2019","unstructured":"Kloppenburg M, Kroon FP, Blanco FJ et al (2019) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis 78:16\u201324. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213826","journal-title":"Ann Rheum Dis"},{"key":"2176_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr.24131","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski SL, Neogi T, Hochberg MC et al (2020) 2019 American college of rheumatology\/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 72:149\u2013162. https:\/\/doi.org\/10.1002\/acr.24131","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE et al (2019) OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27:1578\u20131589. https:\/\/doi.org\/10.1016\/j.joca.2019.06.011","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-018-0095-4","volume":"14","author":"M Marshall","year":"2018","unstructured":"Marshall M, Watt FE, Vincent TL et al (2018) Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol 14:641\u2013656. https:\/\/doi.org\/10.1038\/s41584-018-0095-4","journal-title":"Nat Rev Rheumatol"},{"key":"2176_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.rehab.2016.07.004","volume":"59","author":"A Mobasheri","year":"2016","unstructured":"Mobasheri A, Batt M (2016) An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med 59:333\u2013339. https:\/\/doi.org\/10.1016\/j.rehab.2016.07.004","journal-title":"Ann Phys Rehabil Med"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"e000344","DOI":"10.1136\/rmdopen-2016-000344","volume":"3","author":"A Courties","year":"2017","unstructured":"Courties A, Sellam J, Maheu E et al (2017) Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. RMD Open 3:e000344. https:\/\/doi.org\/10.1136\/rmdopen-2016-000344","journal-title":"RMD Open"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/ard.2011.153965","volume":"71","author":"B Hodkinson","year":"2012","unstructured":"Hodkinson B, Maheu E, Michon M et al (2012) Assessment and determinants of aesthetic discomfort in hand osteoarthritis. Ann Rheum Dis 71:45\u201349. https:\/\/doi.org\/10.1136\/ard.2011.153965","journal-title":"Ann Rheum Dis"},{"key":"2176_CR15","first-page":"64","volume":"37","author":"LA Deveza","year":"2019","unstructured":"Deveza LA, Nelson AE, Loeser RF (2019) Phenotypes of osteoarthritis: current state and future implications. Clin Exp Rheumatol 37:64\u201372","journal-title":"Clin Exp Rheumatol"},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"JH Kellgren","year":"1957","unstructured":"Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494\u2013502. https:\/\/doi.org\/10.1136\/ard.16.4.494","journal-title":"Ann Rheum Dis"},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.joca.2015.11.014","volume":"24","author":"IK Haugen","year":"2016","unstructured":"Haugen IK, Mathiessen A, Slatkowsky-Christensen B et al (2016) Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype? Osteoarthritis Cartilage. 24:647\u2013654. https:\/\/doi.org\/10.1016\/j.joca.2015.11.014","journal-title":"Osteoarthritis Cartilage."},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/art.33502","volume":"64","author":"R Wittoek","year":"2012","unstructured":"Wittoek R, Cruyssen BV, Verbruggen G (2012) Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis. Arthritis Rheum 64:1430\u20131436. https:\/\/doi.org\/10.1002\/art.33502","journal-title":"Arthritis Rheum"},{"key":"2176_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/ard.2007.077081","volume":"67","author":"HI Keen","year":"2008","unstructured":"Keen HI, Lavie F, Wakefield RJ et al (2008) The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis. Ann Rheum Dis 67:651\u2013655. https:\/\/doi.org\/10.1136\/ard.2007.077081","journal-title":"Ann Rheum Dis"},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jhsa.2010.09.003","volume":"35","author":"RA Kaufmann","year":"2010","unstructured":"Kaufmann RA, L\u00f6gters TT, Verbruggen G et al (2010) Osteoarthritis of the distal interphalangeal joint. J Hand Surg 35:2117\u20132125. https:\/\/doi.org\/10.1016\/j.jhsa.2010.09.003","journal-title":"J Hand Surg"},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40520-019-01193-8","volume":"31","author":"M de Wit","year":"2019","unstructured":"de Wit M, Cooper C, Tugwell P et al (2019) Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31:905\u2013915. https:\/\/doi.org\/10.1007\/s40520-019-01193-8","journal-title":"Aging Clin Exp Res"},{"key":"2176_CR22","unstructured":"PREFER. Patient preferences (Innovative Medicines Initiative). https:\/\/www.imi-prefer.eu\/. Accessed Jan 2022"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.semarthrit.2020.08.005","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Dennison E, Beaudart C et al (2020) A discrete-choice experiment to assess patients\u2019 preferences for osteoarthritis treatment: an ESCEO working group. Semin Arthritis Rheum 50:859\u2013866. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.005","journal-title":"Semin Arthritis Rheum"},{"key":"2176_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.joca.2020.07.002","volume":"28","author":"IG Arslan","year":"2020","unstructured":"Arslan IG, Huls SPI, de Bekker-Grob EW et al (2020) Patients\u2019, healthcare providers\u2019, and insurance company employees\u2019 preferences for knee and hip osteoarthritis care: a discrete choice experiment. Osteoarthritis Cartilage 28:1316\u20131324. https:\/\/doi.org\/10.1016\/j.joca.2020.07.002","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.joca.2020.06.006","volume":"28","author":"D Turk","year":"2020","unstructured":"Turk D, Boeri M, Abraham L et al (2020) Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage 28:1202\u20131213. https:\/\/doi.org\/10.1016\/j.joca.2020.06.006","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhsa.2018.03.001","volume":"43","author":"CA Harris","year":"2018","unstructured":"Harris CA, Shauver MJ, Yuan F et al (2018) understanding patient preferences in proximal interphalangeal joint surgery for osteoarthritis: a conjoint analysis. J Hand Surg Am 43:615-624.e614. https:\/\/doi.org\/10.1016\/j.jhsa.2018.03.001","journal-title":"J Hand Surg Am"},{"key":"2176_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01395","author":"E van Overbeeke","year":"2019","unstructured":"van Overbeeke E, Janssens R, Whichello C et al (2019) Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.01395","journal-title":"Front Pharmacol"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0140-6736(19)30034-0","volume":"393","author":"M de Wit","year":"2019","unstructured":"de Wit M, Cooper C, Reginster JY (2019) Practical guidance for patient-centred health research. Lancet 393:1095\u20131096. https:\/\/doi.org\/10.1016\/s0140-6736(19)30034-0","journal-title":"Lancet"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","volume":"49","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re O, Honvo G, Veronese N et al (2019) An updated algorithm recommendation for the management of knee osteoarthritis from the european society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Semin Arthritis Rheum 49:337\u2013350. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.04.008","journal-title":"Semin Arthritis Rheum"},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40520-021-01906-y","volume":"33","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Huang C, Cao Y et al (2021) revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. Aging Clin Exp Res 33:2141\u20132147. https:\/\/doi.org\/10.1007\/s40520-021-01906-y","journal-title":"Aging Clin Exp Res"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40520-021-01834-x","volume":"33","author":"SS Yeap","year":"2021","unstructured":"Yeap SS, Tanavalee A, Perez EC et al (2021) 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. Aging Clin Exp Res 33:1149\u20131156. https:\/\/doi.org\/10.1007\/s40520-021-01834-x","journal-title":"Aging Clin Exp Res"},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"e000734","DOI":"10.1136\/rmdopen-2018-000734","volume":"4","author":"FPB Kroon","year":"2018","unstructured":"Kroon FPB, Carmona L, Schoones JW et al (2018) Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. RMD Open. 4:e000734. https:\/\/doi.org\/10.1136\/rmdopen-2018-000734","journal-title":"RMD Open."},{"key":"2176_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/art.1780331101","volume":"33","author":"R Altman","year":"1990","unstructured":"Altman R, Alarc\u00f3n G, Appelrouth D et al (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33:1601\u20131610. https:\/\/doi.org\/10.1002\/art.1780331101","journal-title":"Arthritis Rheum"},{"key":"2176_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x211022149","author":"C Cadet","year":"2021","unstructured":"Cadet C, Maheu E (2021) Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe? Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720x211022149","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2176_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779. https:\/\/doi.org\/10.1016\/s0140-6736(13)60900-9","journal-title":"Lancet"},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/MEG.0b013e328349de81","volume":"23","author":"X Wang","year":"2011","unstructured":"Wang X, Tian HJ, Yang HK et al (2011) Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 23:876\u2013880. https:\/\/doi.org\/10.1097\/MEG.0b013e328349de81","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2176_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jcpt.12484","volume":"42","author":"BR Gunter","year":"2017","unstructured":"Gunter BR, Butler KA, Wallace RL et al (2017) Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. J Clin Pharm Ther 42:27\u201338. https:\/\/doi.org\/10.1111\/jcpt.12484","journal-title":"J Clin Pharm Ther"},{"key":"2176_CR38","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH et al (2016) Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:2519\u20132529. https:\/\/doi.org\/10.1056\/NEJMoa1611593","journal-title":"N Engl J Med"},{"key":"2176_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40266-019-00664-x","volume":"36","author":"E Curtis","year":"2019","unstructured":"Curtis E, Fuggle N, Shaw S et al (2019) Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36:25\u201344. https:\/\/doi.org\/10.1007\/s40266-019-00664-x","journal-title":"Drugs Aging"},{"key":"2176_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40266-019-00661-0","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Leclercq V, Geerinck A et al (2019) Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36:45\u201364. https:\/\/doi.org\/10.1007\/s40266-019-00661-0","journal-title":"Drugs Aging"},{"key":"2176_CR41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard.2003.018531","volume":"63","author":"W Zhang","year":"2004","unstructured":"Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63:901\u2013907. https:\/\/doi.org\/10.1136\/ard.2003.018531","journal-title":"Ann Rheum Dis"},{"key":"2176_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476\u2013499. https:\/\/doi.org\/10.1016\/j.joca.2010.01.013","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/annrheumdis-2014-206914","volume":"75","author":"E Roberts","year":"2016","unstructured":"Roberts E, Delgado Nunes V, Buckner S et al (2016) Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 75:552\u2013559. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206914","journal-title":"Ann Rheum Dis"},{"key":"2176_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.joca.2009.10.006","volume":"18","author":"EM Bartels","year":"2010","unstructured":"Bartels EM, Bliddal H, Sch\u00f8ndorff PK et al (2010) Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 18:289\u2013296. https:\/\/doi.org\/10.1016\/j.joca.2009.10.006","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR45","first-page":"1787","volume":"34","author":"TE Towheed","year":"2007","unstructured":"Towheed TE, Anastassiades T (2007) Glucosamine therapy for osteoarthritis: an update. J Rheumatol 34:1787\u20131790","journal-title":"J Rheumatol"},{"key":"2176_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005614.pub2","author":"JA Singh","year":"2015","unstructured":"Singh JA, Noorbaloochi S, MacDonald R et al (2015) Chondroitin for osteoarthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005614.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2176_CR47","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/rheumatology\/kem026","volume":"46","author":"JY Reginster","year":"2007","unstructured":"Reginster JY, Bruyere O, Neuprez A (2007) Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford) 46:731\u2013735. https:\/\/doi.org\/10.1093\/rheumatology\/kem026","journal-title":"Rheumatology (Oxford)"},{"key":"2176_CR48","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/acr.22376","volume":"66","author":"P Eriksen","year":"2014","unstructured":"Eriksen P, Bartels EM, Altman RD et al (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 66:1844\u20131855. https:\/\/doi.org\/10.1002\/acr.22376","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2176_CR49","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.joca.2010.02.016","volume":"18","author":"MC Hochberg","year":"2010","unstructured":"Hochberg MC (2010) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 18:S28-31. https:\/\/doi.org\/10.1016\/j.joca.2010.02.016","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40266-019-00662-z","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Reginster JY, Rabenda V et al (2019) Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 36:65\u201399. https:\/\/doi.org\/10.1007\/s40266-019-00662-z","journal-title":"Drugs Aging."},{"key":"2176_CR51","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40520-019-01305-4","volume":"32","author":"S Tenti","year":"2020","unstructured":"Tenti S, Giordano N, Mondanelli N et al (2020) A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res 32:1161\u20131172. https:\/\/doi.org\/10.1007\/s40520-019-01305-4","journal-title":"Aging Clin Exp Res"},{"key":"2176_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clinthera.2013.02.009","volume":"35","author":"K Shin","year":"2013","unstructured":"Shin K, Kim JW, Moon KW et al (2013) The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther 35:431\u2013439. https:\/\/doi.org\/10.1016\/j.clinthera.2013.02.009","journal-title":"Clin Ther"},{"key":"2176_CR53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41584-020-00523-9","volume":"17","author":"NK Arden","year":"2021","unstructured":"Arden NK, Perry TA, Bannuru RR et al (2021) Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol 17:59\u201366. https:\/\/doi.org\/10.1038\/s41584-020-00523-9","journal-title":"Nat Rev Rheumatol"},{"key":"2176_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40520-020-01643-8","volume":"33","author":"JY Reginster","year":"2021","unstructured":"Reginster JY, Veronese N (2021) Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res 33:37\u201347. https:\/\/doi.org\/10.1007\/s40520-020-01643-8","journal-title":"Aging Clin Exp Res"},{"key":"2176_CR55","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10067-002-8290-7","volume":"21","author":"G Verbruggen","year":"2002","unstructured":"Verbruggen G, Goemaere S, Veys EM (2002) Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 21:231\u2013243. https:\/\/doi.org\/10.1007\/s10067-002-8290-7","journal-title":"Clin Rheumatol"},{"key":"2176_CR56","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/art.30574","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay C, Medinger-Sadowski C, Gascon D et al (2011) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 63:3383\u20133391. https:\/\/doi.org\/10.1002\/art.30574","journal-title":"Arthritis Rheum"},{"key":"2176_CR57","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40744-020-00240-5","volume":"7","author":"G Honvo","year":"2020","unstructured":"Honvo G, Lengel\u00e9 L, Charles A et al (2020) Role of collagen derivatives in osteoarthritis and cartilage repair: a systematic scoping review with evidence mapping. Rheumatol Ther 7:703\u2013740. https:\/\/doi.org\/10.1007\/s40744-020-00240-5","journal-title":"Rheumatol Ther"},{"key":"2176_CR58","first-page":"166","volume":"37","author":"E Bartoloni","year":"2019","unstructured":"Bartoloni E, Luccioli F, La Paglia GMC et al (2019) Effect of Sinovial High-Low\u00ae injections in trapeziometacarpal osteoarthritis. Clin Exp Rheumatol 37:166","journal-title":"Clin Exp Rheumatol"},{"key":"2176_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637904","author":"S Tenti","year":"2021","unstructured":"Tenti S, Cheleschi S, Mondanelli N et al (2021) New trends in injection-based therapy for thumb-base osteoarthritis: where are we and where are we going? Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.637904","journal-title":"Front Pharmacol"},{"key":"2176_CR60","doi-asserted-by":"publisher","first-page":"603","DOI":"10.11138\/mltj\/2017.7.4.603","volume":"7","author":"L Rocchi","year":"2017","unstructured":"Rocchi L, Merolli A, Giordani L et al (2017) Trapeziometacarpal joint osteoarthritis: a prospective trial on two widespread conservative therapies. Muscles Ligaments Tendons J 7:603\u2013610. https:\/\/doi.org\/10.11138\/mltj\/2017.7.4.603","journal-title":"Muscles Ligaments Tendons J"},{"key":"2176_CR61","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/1874325000903010048","volume":"3","author":"M Khan","year":"2009","unstructured":"Khan M, Waseem M, Raza A et al (2009) Quantitative assessment of improvement with single corticosteroid injection in thumb cmc joint osteoarthritis? Open Orthop J 3:48\u201351. https:\/\/doi.org\/10.2174\/1874325000903010048","journal-title":"Open Orthop J"},{"key":"2176_CR62","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3899\/jrheum.170424","volume":"44","author":"N \u00d8ster\u00e5s","year":"2017","unstructured":"\u00d8ster\u00e5s N, Kjeken I, Smedslund G et al (2017) Exercise for hand osteoarthritis: a cochrane systematic review. J Rheumatol 44:1850\u20131858. https:\/\/doi.org\/10.3899\/jrheum.170424","journal-title":"J Rheumatol"},{"key":"2176_CR63","doi-asserted-by":"publisher","first-page":"100946","DOI":"10.1016\/j.arr.2019.100946","volume":"55","author":"E Biver","year":"2019","unstructured":"Biver E, Berenbaum F, Valdes AM et al (2019) Gut microbiota and osteoarthritis management: an expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev 55:100946. https:\/\/doi.org\/10.1016\/j.arr.2019.100946","journal-title":"Ageing Res Rev"},{"key":"2176_CR64","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/03009740902913496","volume":"38","author":"B Slatkowsky-Christensen","year":"2009","unstructured":"Slatkowsky-Christensen B, Mowinckel P, Kvien TK (2009) Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis. Scand J Rheumatol 38:342\u2013348. https:\/\/doi.org\/10.1080\/03009740902913496","journal-title":"Scand J Rheumatol"},{"key":"2176_CR65","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","volume":"78","author":"M Kloppenburg","year":"2019","unstructured":"Kloppenburg M, Peterfy C, Haugen IK et al (2019) Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis 78:413\u2013420. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213336","journal-title":"Ann Rheum Dis"},{"key":"2176_CR66","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1136\/annrheumdis-2018-213202","volume":"77","author":"M Kloppenburg","year":"2018","unstructured":"Kloppenburg M, Ramonda R, Bobacz K et al (2018) Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77:1757\u20131764. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213202","journal-title":"Ann Rheum Dis"},{"key":"2176_CR67","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1016\/S2665-9913(20)30171-5","volume":"2","author":"G Schett","year":"2020","unstructured":"Schett G, Bainbridge C, Berkowitz M et al (2020) Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial. Lancet Rheumatol 2:e623\u2013e632. https:\/\/doi.org\/10.1016\/S2665-9913(20)30171-5","journal-title":"Lancet Rheumatol"},{"key":"2176_CR68","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.joca.2018.02.899","volume":"26","author":"D Aitken","year":"2018","unstructured":"Aitken D, Laslett LL, Pan F et al (2018) A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand osteoarthritis - the HUMOR trial. Osteoarthritis Cartilage 26:880\u2013887. https:\/\/doi.org\/10.1016\/j.joca.2018.02.899","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR69","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/annrheumdis-2014-205348","volume":"74","author":"X Chevalier","year":"2015","unstructured":"Chevalier X, Ravaud P, Maheu E et al (2015) Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 74:1697\u20131705. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205348","journal-title":"Ann Rheum Dis"},{"key":"2176_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218547","author":"P Richette","year":"2020","unstructured":"Richette P, Latourte A, Sellam J et al (2020) Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218547","journal-title":"Ann Rheum Dis"},{"key":"2176_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001660","author":"C Kedor","year":"2021","unstructured":"Kedor C, Detert J, Rau R et al (2021) Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001660","journal-title":"RMD Open"},{"key":"2176_CR72","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/m17-1430","volume":"168","author":"SR Kingsbury","year":"2018","unstructured":"Kingsbury SR, Tharmanathan P, Keding A et al (2018) Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med 168:385\u2013395. https:\/\/doi.org\/10.7326\/m17-1430","journal-title":"Ann Intern Med"},{"key":"2176_CR73","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.23471","volume":"70","author":"W Lee","year":"2018","unstructured":"Lee W, Ruijgrok L, Boxma-de Klerk B et al (2018) Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind placebo-controlled trial. Arthritis Care Res (Hoboken) 70:1320\u20131325. https:\/\/doi.org\/10.1002\/acr.23471","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2176_CR74","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.joca.2020.11.002","volume":"29","author":"CR Davis","year":"2021","unstructured":"Davis CR, Ruediger CD, Dyer KA et al (2021) Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage 29:208\u2013214. https:\/\/doi.org\/10.1016\/j.joca.2020.11.002","journal-title":"Osteoarthritis Cartilage"},{"key":"2176_CR75","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.semarthrit.2021.04.016","volume":"51","author":"S Ferrero","year":"2021","unstructured":"Ferrero S, Wittoek R, Allado E et al (2021) Methotrexate treatment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial. Semin Arthritis Rheum 51:831\u2013838. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.016","journal-title":"Semin Arthritis Rheum"},{"key":"2176_CR76","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/s0140-6736(19)32489-4","volume":"394","author":"FPB Kroon","year":"2019","unstructured":"Kroon FPB, Kortekaas MC, Boonen A et al (2019) Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet 394:1993\u20132001. https:\/\/doi.org\/10.1016\/s0140-6736(19)32489-4","journal-title":"Lancet"},{"key":"2176_CR77","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.clinthera.2016.06.016","volume":"38","author":"JK Park","year":"2016","unstructured":"Park JK, Shin K, Kang EH et al (2016) Efficacy and tolerability of GCSB-5 for hand osteoarthritis: a randomized. Controlled Trial Clin Ther 38:1858-1868.e1852. https:\/\/doi.org\/10.1016\/j.clinthera.2016.06.016","journal-title":"Controlled Trial Clin Ther"},{"key":"2176_CR78","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40520-020-01515-1","volume":"32","author":"NR Fuggle","year":"2020","unstructured":"Fuggle NR, Cooper C, Oreffo ROC et al (2020) Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin Exp Res 32:547\u2013560. https:\/\/doi.org\/10.1007\/s40520-020-01515-1","journal-title":"Aging Clin Exp Res"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-022-02176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-022-02176-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-022-02176-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T04:45:36Z","timestamp":1662785136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-022-02176-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":78,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1007\/s40520-022-02176-y","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NB, MCSR, MCPY, FD, CG, GHB, MCH, AL, RM, AM, JPP, RPR, FR, BU, DU, MV, RR, AM and CC report no conflict of interest. OB reports consulting or lecture fees for Amgen, Aptissen, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, Servier, SMB, TRB Chemedica, UCB, Viatris. EMD reports support from Pfizer, UCB, Lilly and Viatris. NF reports educational grants from Pfizer and Eli Lilly. IKH reports consultancies for Novartis and Abbvie, research grant from Pfizer (paid to institution), all outside of the submitted work. MH reports research grant through institution from Amgen, Radius Health, ViiV Healthcare, BD; lecture fees from Teva and Mylan Pharmaceuticals and consulting fees from UCB. EM reports consultancy or speaking fees for Abiogen, Expanscience, Fidia, Meda-Mylan, Pierre Fabre Labs, Sublimed, TRB Chemedica. JYR reports consulting fees or advisory board participation for IBSA-Genevrier, Mylan, Radius Health and Pierre Fabre, lecturing fees for IBSA-Genevrier, Mylan, Cniel and Dairy Research Council (DRC) and grant support from IBSA-Genevrier, Mylan, Cniel and Radius Health. NV reports participation in advisory boards for Mylan, Fidia, Sanofi-Aventis, Viatris, IBSA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a retrospective review. To the authors\u2019 knowledge, the reviewed studies were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this retrospective review, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}